ArticleAmerican journal of ophthalmology case reports2025
A glaucoma drainage implant functioning as a sanctuary site for vitreoretinal lymphoma.
Article in American journal of ophthalmology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To report an unusual case of vitreoretinal lymphoma (VRL) in which a glaucoma drainage implant (GDI) likely functioned as a sanctuary site for relapsing disease. Observations: A 54-year-old female with recently diagnosed CNS diffuse large B-cell lymphoma (DLBCL) was referred for evaluation of VRL. Ocular history at an outside center included a 4-year reported history of uveitis complicated by glaucoma and a GDI in the left eye (OS). Initial examination revealed keratic precipitates (KP), vitreous haze with clumps of white cells OS, and vitreous biopsy revealed DLBCL OS. Intravitreal methotrexate injections were initiated for primary VRL alongside systemic chemotherapy for CNS involvement with resolution of disease. One year later, the patient returned with 2+ anterior chamber (AC) and vitreous cells OS, and vitreous biopsy again revealed DLBCL OS. External radiation treatment was administered for recurrent VRL in the left eye, followed also by the right eye due to the high risk of fellow eye involvement. Autologous stem cell transplantation was then performed. Five months later, the patient returned with worsening KPs and new vitreous cells OS, and vitreous biopsy again revealed DLBCL OS. Enucleation was performed, and histopathology revealed DLBCL cells lining the GDI fibrous capsule, consistent with the GDI likely having served as a sanctuary site and source for continued local relapse. Conclusions and Importance: We report a case in which a GDI functioned as a probable sanctuary site for VRL. Sanctuary sites of malignancy should be considered in patients with pre-existing ocular hardware, particularly when recurrent relapses occur despite complete treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.